The pharmaceutical world is witnessing a significant shift in glucose treatment with the introduction of GLP-1 transdermal devices. These systems offer a seemingly more user-friendly alternative to injections of GLP-1 drugs, minimizing the requirement of daily needle pricks. The technology admini